Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Smith

Showing results (571-580 of 594) with videos related to

Pageof 60
Sort By:
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Human Pathology|June 23, 2024
High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: A single institution experienceBurak Tekin, Antonio L Cubilla, John C Cheville, et al.
JMIR Research Protocols|August 7, 2020
Learning Integrated Health System to Mobilize Context-Adapted Knowledge With a Wiki Platform to Improve the Transitions of Frail Seniors From Hospitals and Emergency Departments to the Community (LEARNING WISDOM): Protocol for a Mixed-Methods Implementation StudyPatrick Michel Archambault, Josée Rivard, Pascal Y Smith, et al.
Human Pathology|November 17, 2023
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinomaBurak Tekin, John C Cheville, Loren Herrera Hernandez, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthMichael S Ominsky, Fay Vlasseros, Jacquelin Jolette, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Human Pathology|May 23, 2024
Comparison of a modified staging system with 8th edition AJCC criteria in a North American cohort of pT2/pT3 HPV-negative penile squamous cell carcinomaBurak Tekin, Akash P Sali, Santosh Menon, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Pageof 60

Showing results (571-580 of 594) with videos related to

Sort By:
Pageof 60
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Human Pathology|June 23, 2024
High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: A single institution experienceBurak Tekin, Antonio L Cubilla, John C Cheville, et al.
JMIR Research Protocols|August 7, 2020
Learning Integrated Health System to Mobilize Context-Adapted Knowledge With a Wiki Platform to Improve the Transitions of Frail Seniors From Hospitals and Emergency Departments to the Community (LEARNING WISDOM): Protocol for a Mixed-Methods Implementation StudyPatrick Michel Archambault, Josée Rivard, Pascal Y Smith, et al.
Human Pathology|November 17, 2023
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinomaBurak Tekin, John C Cheville, Loren Herrera Hernandez, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthMichael S Ominsky, Fay Vlasseros, Jacquelin Jolette, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Human Pathology|May 23, 2024
Comparison of a modified staging system with 8th edition AJCC criteria in a North American cohort of pT2/pT3 HPV-negative penile squamous cell carcinomaBurak Tekin, Akash P Sali, Santosh Menon, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Pageof 60